Table 4.
Comparison of clinical parameters between UMOD positive and negative patients with non-polycystic genetic kidney diseases
| Clinical parameter | UMOD positive | UMOD negative | Significance level (p < 0.0036) |
|---|---|---|---|
| Age at presentation [years] | 9–57, median 39, n = 21 | 0–80, median 35, n = 66 | p = 0.882* |
| Age at RRT [years] | 27–66, median 47, n = 27 | 9–84, median 41, n = 61 | p = 0.116* |
| Gout | 15/33 patients (45%) | 30/78 (38%) | p = 0.493** |
| Allopurinol use | 13/35 patients (37%) | 22/78 (28%) | p = 0.342** |
| Hypertension at presentation | 31/35 patients (89%) | 69/78 (88%) | p = 1.0*** |
| Hyperuricaemia (Uric acid > 0.35 umol/l) | 24/26 patients (92%) | 50/61 patients (82%) | p = 0.328*** |
| Uric Acid [umol/l] | 0.28–0.79, median 0.45, n = 25 | 0.12–0.85, median 0.495, n = 60 | p = 0.155* |
| Proteinuria | 8/22 patients (36%) | 48/62 patients (77%) | p = 0.0004** |
| Protein Creatinine Ratio [mg/g] | 0–2761, median 234.5, n = 18 | 53–20,398, median = 2150, n = 52 | p < 0.001* |
| Anaemia pre RRT (Hb < 100 g/l) | 4/27 patients (15%) | 25/68 patients (37%) | p = 0.036** |
| Microscopic haematuria | 1/27 patients (4%) | 24/63 patients (38%) | p = 0.001** |
| Renal cysts | 4/21 patients (19%) | 6/51 patients (12%) | p = 0.463*** |
| Normal renal size at presentation (renal diameter > 9 cm) | 11/23 patients (48%) | 30/48 patients (63%) | p = 0.241** |
| Electrolyte abnormalities | 6/32 patients (19%) | 2/67 patients (3%) | p = 0.013*** |
A Bonferroni correction was employed to adjust the significance level for the number of performed tests (i.e. the adjusted significance level is p < 0.05/14)
* = Mann Whitney U, ** = χ2, *** = Fisher’s Exact test